A retrospective six-patient series of apatinib for the treatment of persistent or recurrent carcinoma of the cervix

OBJECTIVE: Although advances have been made in the clinical and therapeutic management of women with cervical cancer, the best treatment for patients with metastatic or recurrent cervical cancer is still undefined. Apatinib, a novel inhibitor of vascular endothelial growth factor receptor-2 tyrosine...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Chao, Qin, Shukui, Li, Zixiong, Luo, Xianwen, Zhang, Yu, Zhang, Jue, Liu, Xiufeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6643513/
https://www.ncbi.nlm.nih.gov/pubmed/31410025
http://dx.doi.org/10.2147/OTT.S212536

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6643513/
https://www.ncbi.nlm.nih.gov/pubmed/31410025
http://dx.doi.org/10.2147/OTT.S212536

Ejemplares similares